Skip to main content
PharmAbcine Inc. logo

PharmAbcine Inc. — Investor Relations & Filings

Ticker · 208340 ISIN · KR7208340000 KO Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2020-03-11 AGM Information
Country KR South Korea
Listing KO 208340

About PharmAbcine Inc.

http://pharmabcine.com/

PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the scheduling of a General Meeting of Shareholders on a 'concentrated date' (a date when many companies hold their AGMs). It explains the company's inability to avoid this date due to financial reporting and audit timelines. Since it is a regulatory notification regarding meeting logistics rather than the meeting materials themselves or the results, it falls under the general regulatory filing category.
2020-03-11 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when company insiders (executives or major shareholders) trade company stock. This falls under the category of 'Director's Dealing' (DIRS) as it reports personal share transactions by company executives.
2020-02-25 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the granting of stock options (주식매수선택권 부여). It details the number of shares, exercise price, grant date, and the board resolution details. This type of disclosure regarding equity-based compensation and capital structure changes falls under the 'Regulatory Filings' category as it is a specific corporate disclosure required by the exchange that does not fit into the other specialized categories like 'Director's Dealing' (which is for personal trades) or 'Remuneration Information' (which is typically for executive compensation reports).
2020-02-25 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by the company 'PharmAbcine'. It outlines the date, location, and the agenda items (such as financial statement approval, director appointments, and remuneration limits) to be voted upon. This type of document is a standard proxy solicitation or notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2020-02-25 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service (증권선물위원회) and the Korea Exchange. It details the share acquisition (장내매수) by an executive (Park Hyunsun) of Pharmabcine. This type of filing is a standard regulatory disclosure for insider trading/share ownership changes by company directors or major shareholders, which corresponds to the 'Director's Dealing' category.
2020-02-24 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 95% confidence The document is a regulatory filing from a Korean company (PharmAbcine) announcing a significant change (over 30%) in revenue or profit structure. This is a standard disclosure requirement in the Korean stock market (KRX) for listed companies to report preliminary financial results or significant fluctuations before the final audit is completed. Since it provides key financial highlights (revenue, operating profit, net income) and is an initial announcement of financial performance, it falls under the 'Earnings Release' category. FY 2019
2020-02-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.